Gainers
-
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)
shares jumped 104.7 percent to $94.79 after the company disclosed that its MGL-3196 achieved primary endpoint in patients with
biopsy-proven non-alcoholic steatohepatitis in Phase 2 clinical trial.
-
AeroVironment, Inc. (NASDAQ: AVAV) surged 31.9
percent to $57.05 as the company reported stronger-than-expected earnings for its second quarter on Tuesday.
-
Cleantech Solutions International, Inc. (NASDAQ: CLNT) shares gained 27.5 percent to $6.77 after announcing agreement to acquire
51 percent of Brighten Holdings.
-
Vera Bradley, Inc. (NASDAQ: VRA) shares surged
20.8 percent to $10.44 as the company posted better-than-expected Q3 earnings and raised its FY 2018 earnings guidance.
-
Digital Power Corporation (NYSE: DPW) shares jumped
20.5 percent to $4.3 after gaining 4.87 percent on Tuesday.
-
Viking Therapeutics Inc (NASDAQ: VKTX) shares
gained 18.25 percent to $3.24. Viking Therapeutics announced a common stock offering.
-
GEE Group Inc (NYSE: JOB) shares surged 12.4 percent
to $3.00.
-
U.S. Global Investors, Inc. (NASDAQ: GROW) shares
rose 10.5 percent to $3.78.
-
Davita Inc (NYSE: DVA) climbed 9.6 percent to
$66.79. DaVita Medical Group, a subsidiary of DaVita, agreed to be acquired by Optum for $4.9 billion in cash.
-
Versartis Inc (NASDAQ: VSAR) shares gained 8.6
percent to $2.20.
-
H & R Block Inc (NYSE: HRB) rose 7.3 percent to
$28.22 on upbeat Q2 results.
-
Oxford Industries Inc (NYSE: OXM) shares rose 8
percent to $71.50. Oxford Industries reported upbeat Q3 earnings. However, the company posted downbeat sales for its third
quarter and issued weak FY17 sales guidance.
-
Dave & Buster's Entertainment Inc (NASDAQ: PLAY)
shares gained 6.7 percent to $56.45 after the company reported better-than-expected earnings for its third quarter.
Losers
-
Biocept Inc (NASDAQ: BIOC) declined 34 percent to
$0.76. Biocept priced its 4.93 million share offering at $0.68 per share.
-
Neuralstem, Inc. (NASDAQ: CUR) dropped 26.1
percent to $2.28 after surging 175.89 percent on Tuesday.
-
Tronox Ltd (NYSE: TROX) shares dipped 26 percent to
$18.90. The FTC has challenged Tronox acquisition of Cristal’s titanium dioxide business. Tronox disclosed that it will fight
FTC lawsuit seeking to block proposed acquisition of Saudi-owned Cristal.
-
Fred's, Inc. (NASDAQ: FRED) shares fell 24.7
percent to $3.83. Fred's reported downbeat Q3 results and cancelled its dividend.
-
Cherokee Inc (NASDAQ: CHKE) shares tumbled 22
percent to $2.30 following Q3 results. Cherokee reported Q3 adjusted loss of $0.05 per share on sales of $11.0 million.
-
Valhi, Inc. (NYSE: VHI) shares dipped 20.8 percent
to $5.71.
-
Bill Barrett Corporation (NYSE: BBG) shares declined
18.6 percent to $4.66. Bill Barrett reported a 21 million share offering and announced a strategic combination with Fifth Creek
Energy in a $649 million transaction.
-
Wins Finance Holdings Inc (NASDAQ: WINS) shares
dipped 17.5 percent to $68.41.
-
Liquidity Services, Inc. (NASDAQ: LQDT) shares
fell 16.5 percent to $4.80 on weaker-than-expected quarterly results.
-
CASI Pharmaceuticals Inc (NASDAQ: CASI) shares
dropped 16 percent to $3.36.
-
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares
fell 12.30 percent to $11.42
-
Kronos Worldwide, Inc. (NYSE: KRO) shares slipped
12.11 percent to $23.96.
-
Timkensteel Corp (NYSE: TMST) shares dropped 11.3
percent to $13.23. KeyBanc downgraded TimkenSteel from Sector Weight to Underweight.
-
Attunity Ltd. (NASDAQ: ATTU) fell 10.1 percent to
$6.50. Attunity priced its 2.96 million share offering at $6.75 per share.
-
Editas Medicine Inc (NASDAQ: EDIT) slipped 9.3
percent to $24.76 as the company reported a $50 million stock offering.
-
Veeva Systems Inc (NYSE: VEEV) slipped 6.6 percent
to $53.96, despite reporting a third quarter earnings and sales beat. The company also issued fourth quarter earnings guidance
ahead of estimates.
-
Patterson Companies, Inc. (NASDAQ: PDCO) tumbled
5.5 percent to $34.32. Morgan Stanley downgraded Patterson Companies from Equal-Weight to Underweight.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.